Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ODC-IL2
- Development stage
- Phase 1
- Lead developer
- Trutino Biosciences
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
ODC-IL2 is a conditionally activated interleukin-2 (IL-2) prodrug developed by Trutino Biosciences for the treatment of advanced or metastatic solid tumors. It is designed using Trutino’s On-Demand-Cytokine (ODC) platform to be systemically delivered in an inactive form and locally activated at the tumor site. This approach aims to maximize immune activation against cancer cells while minimizing systemic toxicity commonly associated with conventional cytokine therapies. Mechanistically, ODC-IL2 acts as an agonist of the interleukin-2 receptor (IL-2R), stimulating T cell and natural killer (NK) cell proliferation and activity within the tumor microenvironment. The drug is currently being evaluated in Phase I clinical trials as a single agent administered intravenously[1][3][5][8].
- Other names
- ODC Interleukin-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on ODC-IL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ODC-IL2.